By Paul Armentano, norml.org
A naturally occurring analogue of THC — tetrahydrocannabivarin (THCV) — has positive metabolic effects in animal models of obesity, according to preclinical study data published online in June in the scientific journal Nutrition & Diabetes.
British researchers assessed the effects of THCV administration on dietary-induced and genetically modified obese mice. Authors reported that although its administration did not significantly affect food intake or body weight gain in any of the models, it did produce several metabolically beneficial effects, including reduced glucose intolerance, improved glucose tolerance, improved liver triglyceride levels, and increased insulin sensitivity.
Researchers concluded: “Based on these data, it can be suggested that THCV may be useful for the treatment of the metabolic syndrome and/or type 2 diabetes (adult onset diabetes), either alone or in combination with existing treatments. Given the reported benefits of another non-THC cannabinoid, CBD in type 1 diabetes, a CBD/THCV combination
Read More: Cannabinoids may halt diabetes
